04.22.10
Genzyme 1Q10
1Q Revenues: $1.1 billion (-7%)
1Q Loss: $115 million (earnings of $196 million in 1Q09)
Comments: Revenues were impacted by the shutdown of the Allston manufacturing facility. Cerezyme sales were down 40% to $179 million. Fabrazyme sales dropped from $122 million to $53 million. Myozyme sales were up 28% to $86 million. For more on the company's consent decreee with the FDA , see this story.
1Q Revenues: $1.1 billion (-7%)
1Q Loss: $115 million (earnings of $196 million in 1Q09)
Comments: Revenues were impacted by the shutdown of the Allston manufacturing facility. Cerezyme sales were down 40% to $179 million. Fabrazyme sales dropped from $122 million to $53 million. Myozyme sales were up 28% to $86 million. For more on the company's consent decreee with the FDA , see this story.
